National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$33.00
add to cart

Rights & Permissions

topleft topright

An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program (2002)
Medical Follow-Up Agency (MFUA)
Institute of Medicine (IOM)

Citation Manager

. "Appendix B: Information-Gathering Meeting Agendas." An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington, DC: The National Academies Press, 2002.

Please select a format:

BibTeX EndNote RefMan


Page
106
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


10:00

Vaccine Adverse Events Reporting System (VAERS) background

Gina Mootrey, D.O., M.P.H., Senior Research Officer, Vaccine Safety Development Activity, Epidemiology and Surveillance Division, National Immunization Program, CDC

M. Miles Braun, M.D., M.P.H., Division of Epidemiology, Office of Biostatistics & Epidemiology, Center for Biologics Evaluation and Research, FDA

10:30

Break

10:45

Background on Anthrax Vaccine Expert Committee (AVEC)

Vito Caserta, M.D., M.P.H., National Vaccine Injury Compensation Program, Health Resources and Services Administration, DHHS

11:00

Sponsor overview of CDC research program

Benjamin Schwartz, M.D., Acting Director, Epidemiology & Surveillance Division, National Immunization Program, CDC

Michael M. McNeil, M.D., M.P.H., Chief, Anthrax Vaccine Safety Activity, Epidemiology & Surveillance Division, National Immunization Program

Kristine Sheedy, Ph.D., Health Communication Specialist, Vaccine Safety Development Activity, Epidemiology & Surveillance Division, National Immunization Program

Gina Mootrey, D.O., M.P.H., Senior Research Officer, Vaccine Safety Development Activity, Epidemiology & Surveillance Division, National Immunization Program

12:15 p.m.

Lunch

1:15

Sponsor overview of CDC research program, continued

Bradley A. Perkins, M.D., National Center for Infectious Diseases, CDC

2:00

Adjourn

Meeting II February 8, 2001

The Foundry Building 1055 Thomas Jefferson Street, NW Washington, DC

Agenda

Open Session

9:00 a.m.

Welcome, introductory remarks, and introductions by committee members and meeting attendees

Philip Brachman, M.D., Chairman, Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program

9:15

Review of charge

Philip Brachman, M.D.

Page
106